Recommendations about add-on reimbursement for medical devices in France in February 2023

07

Mar 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in February 2023. Twenty-eight recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, neurovascular, ophthalmological, spine, and orthopedic devices, surgical procedures, as well as medical aids.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Some examples of the recommendations are provided below.

  • Subcutaneous defibrillation lead EMBLEM MRI S-ICD (MODÈLE 3501) by BOSTON SCIENTIFIC (application for renewal of registration; sufficient actual benefit; level V or level III of Clinical Added Value (ASA), depending on the indications or comparator);
  • Abdominal aortic stent graft ZENITH FLEX by COOK (application for renewal of registration; sufficient actual benefit; level V of clinical added value compared to other abdominal aortic stents listed on the LPPR);
  • Peripheral sirolimus-eluting stent NITIDES by ALVIMEDICA (application for registration; sufficient actual benefit; level V of clinical added value compared to other drug-eluting peripheral stents listed on the LPPR);
  • Paclitaxel-coated peripheral balloon RANGER by BOSTON SCIENTIFIC (application for renewal of registration; sufficient actual benefit; level IV of clinical added value compared to the bare balloon).
  • Self-expanding intracranial stent CERENOVUS ENTERPRISE 2 by JOHNSON & JOHNSON (application for renewal of registration; sufficient actual benefit; level V of clinical added value compared to other intracranial stents listed on the LPPR and used in identical indications).
  • Aqueous humor drainage system PRESERFLO MICROSHUNT by SANTEN (application for registration; sufficient actual benefit; level IV of clinical added value compared to other conventional filtering surgeries (trabeculectomy, sclerectomy)).
  • Growth implant with self-expanding domino NEMOST by EUROS (application for registration; sufficient actual benefit; level II of clinical added value compared to growth rods with classic domino).

Also, recommendations were made in relation to orthopedic devices, surgical procedures, and a number of medical aids.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Mar 2023

On March 2, 2023, the decision of the National Union of Health Insurance Funds relating to the update of the CCAM Nomenclature of procedure codes was published in the Official Journal of the French Republic. Changes include registration of new procedure codes, modification and removal of some existing codes. Newly introduced codes concern cardiovascular procedures, interventional radiology, orthopedics, peripheral vascular procedures, and others.

Read more

22

Mar 2023

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

Read more

21

Mar 2023

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system for lung volume reduction under Forfait innovation program.

Read more

20

Mar 2023

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics. Twelve new codes concerning clinical biology, molecular biology for infections, and genetics were implemented.

Read more

13

Mar 2023

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 3844 of March 02, 2023, Tuscany Regional Healthcare has published assessments of four medical devices in the cardiovascular and neurovascular treatment areas.

Read more